(0.24%) 5 112.43 points
(0.28%) 38 345 points
(0.28%) 15 972 points
(-1.03%) $82.99
(5.67%) $2.03
(0.37%) $2 355.80
(0.46%) $27.66
(4.44%) $963.05
(-0.26%) $0.932
(-0.40%) $10.98
(-0.54%) $0.796
(1.68%) $93.42
3 days till quarter result
(bmo 2024-05-02)
Expected move: +/- 7.54%
@ $1.790
发出时间: 14 Feb 2024 @ 22:30
回报率: 26.26%
上一信号: Feb 13 - 22:30
上一信号:
回报率: 1.71 %
Live Chart Being Loaded With Signals
Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate population of T cells with durable stemness...
Stats | |
---|---|
今日成交量 | 165 248 |
平均成交量 | 911 022 |
市值 | 576.16M |
EPS | $0 ( 2024-02-27 ) |
下一个收益日期 | ( $-0.200 ) 2024-05-02 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -2.43 |
ATR14 | $0.00500 (0.22%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-02-09 | Lang Matthew | Buy | 500 000 | Option (right to buy) |
2024-02-09 | Lang Matthew | Buy | 50 000 | Common Stock |
2024-02-09 | Hill Stephen J. | Buy | 400 000 | Stock Option (right to buy) |
2024-02-09 | Hill Stephen J. | Buy | 40 000 | Common Stock |
2024-02-09 | Lee Gary K. | Buy | 400 000 | Stock Option (right to buy) |
INSIDER POWER |
---|
39.75 |
Last 94 transactions |
Buy: 113 687 542 | Sell: 91 558 207 |
音量 相关性
Lyell Immunopharma, Inc. 相关性
10 最正相关 |
---|
10 最负相关 |
---|
你知道吗?
相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1,其中-1表示完全负相关(一个变量增加,另一个变量减少),1表示完全正相关(一个变量增加,另一个变量也增加),0表示没有相关性(变量之间没有关系)。
相关性可用于分析任何两个变量之间的关系,而不仅仅是股票。它通常用于金融、经济学、心理学等领域。
Lyell Immunopharma, Inc. 相关性 - 货币/商品
Lyell Immunopharma, Inc. 财务报表
Annual | 2023 |
营收: | $130 000 |
毛利润: | $-20.12M (-15 476.92 %) |
EPS: | $-0.930 |
FY | 2023 |
营收: | $130 000 |
毛利润: | $-20.12M (-15 476.92 %) |
EPS: | $-0.930 |
FY | 2022 |
营收: | $84.68M |
毛利润: | $68.22M (80.55 %) |
EPS: | $-0.0192 |
FY | 2021 |
营收: | $10.65M |
毛利润: | $10.65M (100.00 %) |
EPS: | $-1.249 |
Financial Reports:
No articles found.
Lyell Immunopharma, Inc.
Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate population of T cells with durable stemness. Its pipeline includes LYL797, a T cell product candidate for the treatment of non-small cell lung cancer and triple negative breast cancers; LYL845, that targets multiple solid tumors; and NY-ESO-1 for synovial sarcoma and other solid tumor indications. The company entered into research and development collaboration and license agreement with GlaxoSmithKline for NY-ESO-1 program. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。